3 Reasons to Buy This Biotech Stock

MGTA is assailing new heights after Raymond James initiated coverage

by Andrea Kramer

Published on Mar 15, 2019 at 3:00 PM

Magenta Therapeutics Inc (NASDAQ:MGTA) is among the best Nasdaq stocks today, thanks to some upbeat analyst attention. Specifically, Raymond James launched coverage of the biotech stock with an "outperform" rating and $22 price target -- representing a 60% premium to Thursday's close. The analyst gave three reasons for the bullish initiation: encouraging clinical results -- and "an opportunity to significantly increase the utilization" of -- its MGTA-456 stem cell therapy; the prospects for MGTA-145; and the potential for Magenta's C200 to alleviate headwinds for cell-based gene therapies.

MGTA shares were last seen 27.8% higher at $17.52, and earlier touched an all-time high of $17.95. Today's rally has the stock barreling through former resistance in the $16-$16.50 neighborhood, which has contained most advances since its initial public offering (IPO) -- priced at $15 -- and debut in June.

Considering the shares have more than tripled since their record low of $5.31 on Dec. 28, it's not surprising that most analysts are already bullish on MGTA. The stock currently boasts five "buy" or better ratings, with not a single "hold" or "sell" in sight. However, some price-target hikes could be in store, as the consensus 12-month price target of $20.33 now represents just a 16% premium to current levels.

What's more, a short squeeze could be in effect. Short interest accounts for more than 5% of MGTA's total available float, representing more than three weeks' of pent-up buying demand, at the security's average pace of trading.

 


a schaeffer's exclusive

5 HOT STOCK PICKS

Heat up your summer trading with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Future of Marijuana is in the "Priceline of Pot"
Click to continue to advertiser's site.
3 Solar Stocks Shining on Analyst Upgrades
Goldman Sachs just upgraded several stocks in the solar energy sector
Bull Notes for Snap, Pinterest Stocks
It's a big morning for social media stocks
The Future of Marijuana is in the "Priceline of Pot"
Click to continue to advertiser's site.